Jazz Pharmaceuticals Financial Ratios
NASDAQ: JAZZHealth CareBiotechnology: Pharmaceutical PreparationsUSD
218.42-4.03 (-1.81%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Jazz Pharmaceuticals ratio analysis
Jazz Pharmaceuticals earned a net margin of -8.3% in FY 2025, down from 13.8% a year earlier. Return on equity reached -8.2%, meaning Jazz Pharmaceuticals generated -0.08 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 1.24 versus 1.49 the year before, and the current ratio was 1.86.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Jazz Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | 13.94 | 20.16 | — | — | 39.11 | 16.07 | 17.64 | 16.92 | 17.01 |
| Price / sales | 2.47 | 1.83 | 2.03 | 2.72 | 2.46 | 3.89 | 3.84 | 4.08 | 4.99 | 4.43 |
| Price / book | 2.44 | 1.82 | 2.08 | 3.23 | 1.92 | 2.51 | 2.66 | 2.80 | 2.98 | 3.51 |
| Operating margin | -10.1% | 17.6% | 15.1% | -1.8% | 5.5% | 16.0% | 24.6% | 32.5% | 32.7% | 39.8% |
| Net margin | -8.3% | 13.8% | 10.8% | -6.1% | -10.7% | 10.1% | 24.2% | 23.6% | 30.1% | 26.7% |
| Free cash flow margin | 30.4% | 33.4% | 27.9% | 34.0% | 24.3% | 37.4% | 34.1% | 41.2% | 41.0% | 39.2% |
| Return on equity (ROE) | -8.2% | 13.7% | 11.1% | -7.3% | -8.3% | 6.5% | 16.8% | 16.2% | 18.0% | 21.1% |
| Return on assets (ROA) | -3.1% | 4.7% | 3.6% | -2.1% | -2.7% | 3.7% | 9.4% | 8.6% | 9.5% | 8.3% |
| Debt / equity | 1.24 | 1.49 | 1.53 | 1.86 | 1.53 | 0.57 | 0.52 | 0.58 | 0.58 | 1.08 |
| Current ratio | 1.86 | 4.46 | 2.24 | 2.79 | 3.23 | 4.34 | 4.47 | 3.57 | 3.29 | 2.91 |
| Revenue growth | 4.9% | 6.1% | 4.8% | 18.3% | 30.9% | 9.3% | 14.3% | 16.8% | 8.8% | 12.3% |
| EPS growth | -167.5% | 41.8% | — | — | -230.8% | -53.6% | 24.5% | -8.3% | 24.2% | 22.6% |